Home

Footer

DeepDyve Logo
FacebookTwitter

Features

  • Search and discover articles on DeepDyve, PubMed, and Google Scholar
  • Read the full-text of open access and premium content
  • Organize articles with folders and bookmarks
  • Collaborate on and share articles and folders

Info

  • Pricing
  • Enterprise Plans
  • Browse Journals & Topics
  • About DeepDyve

Help

  • Help
  • Publishers
  • Contact Us

Popular Topics

  • COVID-19
  • Climate Change
  • Biopharmaceuticals
Terms |
Privacy |
Security |
Help |
Enterprise Plans |
Contact Us

Select data courtesy of the U.S. National Library of Medicine.

© 2023 DeepDyve, Inc. All rights reserved.

CNS Drugs

Subject:
Neurology (clinical)
Publisher:
Springer International Publishing —
Springer Journals
ISSN:
1172-7047
Scimago Journal Rank:
115

2023

Volume OnlineFirst
SeptemberAugust
Volume 37
Issue 9 (Sep)Issue 8 (Aug)Issue 7 (Jul)Issue 6 (Jun)Issue 5 (May)Issue 4 (Apr)Issue 3 (Mar)Issue 2 (Feb)Issue 1 (Jan)

2022

Volume 36
Issue 12 (Dec)Issue 11 (Nov)Issue 10 (Oct)Issue 9 (Sep)Issue 8 (Aug)Issue 7 (Jul)Issue 6 (Jun)Issue 5 (May)Issue 4 (Apr)Issue 3 (Mar)Issue 2 (Feb)Issue 1 (Jan)

2021

Volume 35
Issue 12 (Dec)Issue 11 (Nov)Issue 10 (Oct)Issue 9 (Sep)Issue 8 (Jul)Issue 7 (Jul)Issue 6 (May)Issue 5 (Apr)Issue 4 (Apr)Issue 3 (Mar)Issue 2 (Feb)Issue 1 (Jan)

2020

Volume 34
Issue 12 (Nov)Issue 11 (Nov)Issue 10 (Oct)Issue 9 (Sep)Issue 8 (Aug)Issue 7 (Jul)Issue 6 (Jun)Issue 5 (May)Issue 4 (Apr)Issue 3 (Mar)Issue 2 (Feb)Issue 1 (Jan)

2019

Volume 33
Issue 12 (Nov)Issue 11 (Nov)Issue 10 (Oct)Issue 9 (Aug)Issue 8 (Jul)Issue 7 (Jun)Issue 6 (Apr)Issue 5 (Apr)Issue 4 (Mar)Issue 3 (Feb)Issue 2 (Jan)

2018

Volume 33
Issue 3 (Dec)Issue 2 (Dec)Issue 1 (Dec)
Volume 32
Issue 12 (Nov)Issue 11 (Oct)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Jun)Issue 6 (May)Issue 5 (May)Issue 4 (Mar)Issue 3 (Mar)Issue 2 (Mar)Issue 1 (Jan)

2017

Volume 32
Issue 1 (Dec)
Volume 31
Issue 12 (Dec)Issue 11 (Oct)Issue 10 (Oct)Issue 9 (Aug)Issue 8 (Jul)Issue 7 (Jun)Issue 6 (May)Issue 5 (Apr)Issue 4 (Mar)Issue 3 (Feb)Issue 2 (Jan)

2016

Volume 31
Issue 3 (Nov)Issue 2 (Dec)Issue 1 (Nov)
Volume 30
Issue 12 (Nov)Issue 11 (Jul)Issue 10 (Aug)Issue 9 (Jul)Issue 8 (Jul)Issue 7 (Jun)Issue 6 (May)Issue 5 (Apr)Issue 4 (Apr)Issue 3 (Feb)Issue 2 (Feb)Issue 1 (Jan)

2015

Volume 30
Issue 2 (Dec)Issue 1 (Dec)
Volume 29
Issue 12 (Nov)Issue 11 (Oct)Issue 10 (Oct)Issue 9 (Sep)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Jul)Issue 5 (Apr)Issue 4 (Apr)Issue 3 (Feb)Issue 2 (Feb)Issue 1 (Jan)

2014

Volume 29
Issue 2 (Dec)Issue 1 (Nov)
Volume 28
Issue 12 (Nov)Issue 11 (Oct)Issue 10 (Jun)Issue 9 (Aug)Issue 8 (May)Issue 7 (May)Issue 6 (May)Issue 5 (Mar)Issue 4 (Feb)Issue 3 (Feb)Issue 2 (Jan)

2013

Volume 28
Issue 2 (Dec)Issue 1 (Dec)
Volume 27
Issue 12 (Nov)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Jun)Issue 7 (Jun)Issue 6 (May)Issue 5 (Apr)Issue 4 (Mar)Issue 3 (Feb)Issue 2 (Jan)Issue 1 (May)

2012

Volume 27
Issue 2 (Oct)Issue 1 (Dec)
Volume 26
Issue 12 (Oct)Issue 11 (Sep)Issue 10 (Dec)Issue 9 (Dec)Issue 8 (Dec)Issue 7 (Dec)Issue 6 (Dec)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 25
Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Dec)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 24
Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Sep)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 23
Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 22
Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Sep)Issue 6 (Sep)Issue 5 (Sep)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 21
Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Sep)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 20
Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 19
Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 18
Issue 15 (Aug)Issue 14 (Aug)Issue 13 (Aug)Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 17
Issue 15 (Aug)Issue 14 (Aug)Issue 13 (Aug)Issue 12 (Aug)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 16
Issue 12 (Sep)Issue 11 (Aug)Issue 10 (Aug)Issue 9 (Aug)Issue 8 (Aug)Issue 7 (Aug)Issue 6 (Aug)Issue 5 (Sep)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 15
Issue 12 (Sep)Issue 11 (Sep)Issue 10 (Aug)Issue 9 (Sep)Issue 8 (Sep)Issue 7 (Sep)Issue 6 (Sep)Issue 5 (Sep)Issue 4 (Sep)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 14
Issue 6 (Sep)Issue 5 (Aug)Issue 4 (Sep)Issue 3 (Sep)Issue 2 (Sep)Issue 1 (Sep)
Volume 13
Issue 6 (Sep)Issue 5 (Sep)Issue 4 (Sep)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 12
Issue 6 (Sep)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Sep)
Volume 11
Issue 6 (Aug)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 10
Issue 6 (Sep)Issue 5 (Aug)Issue 4 (Aug)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 9
Issue 6 (Sep)Issue 5 (Aug)Issue 4 (Oct)Issue 3 (Aug)Issue 2 (Aug)Issue 1 (Aug)
Volume 8
Issue 6 (Dec)Issue 5 (Oct)Issue 4 (Oct)Issue 3 (Nov)Issue 2 (Oct)Issue 1 (Oct)
Volume 7
Issue 6 (Nov)Issue 5 (Nov)Issue 4 (Oct)Issue 3 (Oct)Issue 2 (Oct)Issue 1 (Oct)
Volume 6
Issue 6 (Nov)Issue 5 (Oct)Issue 4 (Nov)Issue 3 (Nov)Issue 2 (Nov)Issue 1 (Nov)
Volume 5
Issue 6 (Nov)Issue 5 (Nov)Issue 4 (Nov)Issue 3 (Oct)Issue 2 (Oct)Issue 1 (Nov)
Volume 4
Issue 6 (Nov)Issue 5 (Oct)Issue 4 (Nov)Issue 3 (Oct)Issue 2 (Oct)Issue 1 (Oct)
Volume 3
Issue 6 (Oct)Issue 5 (Nov)Issue 4 (Oct)Issue 3 (Oct)Issue 2 (Nov)Issue 1 (Nov)
Volume 2
Issue 6 (Oct)Issue 5 (Oct)Issue 4 (Oct)Issue 3 (Oct)Issue 2 (Oct)Issue 1 (Oct)
Volume 1
Issue 6 (Oct)Issue 5 (Oct)Issue 4 (Nov)Issue 3 (Nov)Issue 2 (Oct)Issue 1 (Nov)

2008

Volume 22
Issue 3 (Mar)

1996

Volume 5
Issue 6 (Jun)
journal article
LitStream Collection
Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”

Pande, Uday; Gaikwad, Nitin R.; Singh, Alok

2023 CNS Drugs

doi: 10.1007/s40263-023-01034-3pmid: 37656358

journal article
LitStream Collection
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies

Prosperini, Luca; Haggiag, Shalom; Ruggieri, Serena; Tortorella, Carla; Gasperini, Claudio

2023 CNS Drugs

doi: 10.1007/s40263-023-01038-zpmid: 37740822

BackgroundThe question of whether multiple sclerosis requires life-long disease-modifying treatments (DMTs) remains unanswered. Some studies suggest that older patients with stable disease may safely discontinue their DMTs, yet comprehensive evidence-based data are scarce and real-world studies have provided mixed results.ObjectiveThe aim of this study was to assess the rate of disease reactivation and associated risk factors after discontinuation of DMTs in patients with multiple sclerosis.MethodsWe searched scientific databases (PubMed/MEDLINE, Scopus and Google Scholar) to identify real-world studies published until 31 July, 2023 that reported the number of patients who experienced relapses and/or disability accrual (outcomes of interest) following a therapy discontinuation longer than 12 months. Magnetic resonance activity and treatment re-start after DMT discontinuation were also considered as additional outcomes. We excluded studies where therapy discontinuation was explicitly related to an unintended or planned pregnancy or preceded a treatment switch. We ran random-effects meta-analyses, subgroup analyses and meta-regression models to provide pooled estimates of post-discontinuation relapse and disability events, and to identify their potential moderators (predictors).ResultsAfter an independent screening, 22 articles met the eligibility criteria, yielding a pooled sample size of 2942 patients followed for 1–7 years after discontinuation (11,689 patient-years). The pooled rates for relapse and disability events were 6.7 and 5.8 per 100 patient-years, respectively. However, available data did not allow us to disentangle isolated disability accrual from relapse-associated worsening. Studies including older patients (β = −0.65, p = 0.006), patients with a longer exposure to DMTs (β = −2.22, p = 0.001) and patients with a longer period of disease stability (β = −2.74, p = 0.002) showed a lower risk of relapse events. According to meta-regression equations, the risk of relapse events after DMT discontinuation became negligible (arbitrarily set at < 1% per year) at approximately 60 years of age, and after either 10 years of DMT exposure, or 8 years of disease stability. Additional analyses showed pooled rates for magnetic resonance imaging activity and re-start events of 16.7 and 17.5 per 100 patient-years, respectively.ConclusionsBased on our quantitative synthesis of real-world data, in the absence of definitive answers from clinical trials, DMT discontinuation appears feasible with a high degree of certainty in selected patients. While our findings are robust regarding relapse events, future efforts are warranted to determine if DMT discontinuation is associated with isolated disability accrual.
journal article
LitStream Collection
Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”

Price, Maxwell Z.; Price, Richard L.

2023 CNS Drugs

doi: 10.1007/s40263-023-01035-2pmid: 37656357

journal article
LitStream Collection
Assisted Reproductive Technology and Disease Management in Infertile Women with Multiple Sclerosis

Sparaco, Maddalena; Carbone, Luigi; Landi, Doriana; Ingrasciotta, Ylenia; Di Girolamo, Raffaella; Vitturi, Giacomo; Marfia, Girolama Alessandra; Alviggi, Carlo; Bonavita, Simona

2023 CNS Drugs

doi: 10.1007/s40263-023-01036-1pmid: 37679579

Multiple sclerosis (MS) predominantly affects women of fertile age. Various aspects of MS could impact on fertility, such as sexual dysfunction, endocrine alterations, autoimmune imbalances, and disease-modifying therapies (DMTs). The proportion of women with MS (wMS) requesting infertility management and assisted reproductive technology (ART) is increasing over time. In this review, we report on data regarding ART in wMS and address safety issues. We also discuss the clinical aspects to consider when planning a course of treatment for infertility, and provide updated recommendations to guide neurologists in the management of wMS undergoing ART, with the goal of reducing the risk of disease activation after this procedure. According to most studies, there is an increase in relapse rate and magnetic resonance imaging activity after ART. Therefore, to reduce the risk of relapse, ART should be considered in wMS with stable disease. In wMS, especially those with high disease activity, fertility issues should be discussed early as the choice of DMT, and fertility preservation strategies might be proposed in selected cases to ensure both disease control and a safe pregnancy. For patients with stable disease taking DMTs compatible with pregnancy, treatment should not be interrupted before ART. If the ongoing therapy is contraindicated in pregnancy, then it should be switched to a compatible therapy. Prior to beginning fertility treatments in wMS, it would be reasonable to assess vitamin D serum levels, thyroid function and its antibody serum levels; start folic acid supplementation; and ensure smoking and alcohol cessation, adequate sleep, and food hygiene. Cervico-vaginal swabs for Ureaplasma urealyticum, Mycoplasma hominis, and Chlamydia trachomatis, as well as serology for viral hepatitis, HIV, syphilis, and cytomegalovirus, should be performed. Steroids could be administered under specific indications. Although the available data do not clearly show a definite raised relapse risk associated with a specific ART protocol, it seems reasonably safe to prefer the use of gonadotropin-releasing hormone (GnRH) antagonists for ovarian stimulation. Close clinical and radiological monitoring is reasonably recommended, particularly after hormonal stimulation and in case of pregnancy failure.
Browse All Journals

Related Journals:

NeurologyJAMA NeurologyJournal of Spinal Cord MedicineCurrent Treatment Options in NeurologyNeurology: Clinical PracticeNeurohospitalist, TheCerebellum and AtaxiasCase Reports in NeurologyCephalalgia Reports